Filing Flows › Arrowhead Pharmaceuticals (ARWR) › Q3 FY26 › vs Q2 FY26
Arrowhead Pharmaceuticals (ARWR) Q3 FY26 vs Q2 FY26 (quarter over quarter)
Arrowhead Pharmaceuticals's revenue rose $1.5M (+2%) from $73.7M in Q2 FY26 to $75.3M in Q3 FY26.
Arrowhead Pharmaceuticals, Q3 FY26: revenue $75.3M (+171% year over year), operating margin -226.0%, net loss $179M, operating cash flow −$177M. The chart draws each line against Q2 FY26, the increases inside each band.
Every line
| Line | Q3 FY26 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $75.3M | $73.7M | $1.5M | +2% |
| Net loss | $179M | $138M | $41.3M | +30% |
| Costs & expenses | $254M | $215M | $39.2M | +18% |
| Operating costs | $245M | $215M | $30.3M | +14% |
| Interest & other, net | $8.8M | −$3.7M | $12.5M | — |
| Income tax | $11K | $7K | $4K | +57% |
| Research & development | $198M | $173M | $25.0M | +14% |
| SG&A | $47.1M | $41.7M | $5.4M | +13% |
| Operating cash sources | $199M | −$61.9M | $260M | — |
| Depreciation & amortization | $6.2M | $5.9M | $300K | +5% |
| Share-based compensation | $14.9M | $16.7M | −$1.8M | -11% |
| Cash used in operations | $177M | −$84.4M | $262M | — |
| Net loss absorbed | $179M | $138M | $41.3M | +30% |
| Working capital & other | $19.6M | −$199M | $219M | — |
Questions
How much did Arrowhead Pharmaceuticals's revenue grow quarter over quarter in Q3 FY26?
Arrowhead Pharmaceuticals's revenue rose $1.5M (+2%) from $73.7M in Q2 FY26 to $75.3M in Q3 FY26.